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Abstract 
Background: Diffuse large B cell lymphoma (DLBCL) contains heterogeneous subtypes with various molecular dys‑
regulation at the gene, protein and microRNA levels. Compared with the GCB subtype, the non‑germinal center B‑like 
(non‑GCB)/activated B cell‑like (ABC) subtype exhibits frequent progression despite standard immunochemotherapy. 
We aimed to investigate the effects of miR‑197 on the progression and chemosensitivity of DLBCL with respect to the 
GCB and non‑GCB/ABC subtypes.
Methods: To screen distinctively expressed microRNAs, microRNA expression patterns were analyzed in 10 DLBCL 
cases by microarray chip assays. Using quantitative real‑time polymerase chain reaction (qRT‑PCR), associations 
between miR‑197 expression levels and clinicopathologic variables were investigated in 51 DLBCL tissue samples. The 
effects of miR‑197 on doxorubicin chemosensitivity were investigated using the OCI‑Ly1 and SUDHL9 cell lines.
Results: MicroRNA expression profiling by hierarchical clustering revealed that miR‑197 was one of the distinctively 
expressed microRNAs in DLBCL. Quantitative analysis using qRT‑PCR revealed that miR‑197 levels were not cor‑
related with clinicopathologic variables, including the international prognostic index, but low miR‑197 levels were 
significantly associated with lymphoma progression defined by refractoriness, relapse or death in the rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑CHOP)‑treated subgroup (n = 43; p = 0.004). Among 
the three molecular groups, i.e., the GCB, non‑GCB/miR‑197low and non‑GCB/miR‑197high groups, progression was 
most frequently observed in the non‑GCB/miR‑197low group in the full cohort (p = 0.013) and the R‑CHOP cohort 
(p = 0.008). In survival analysis, low miR‑197 levels were independently predictive of shorter progression‑free survival 
in the R‑CHOP cohort (p = 0.031; HR = 27.9) and the non‑GCB subgroup (p = 0.037; HR = 21.5) but not in the GCB 
subgroup. Using SUDHL9 (ABC type) and OCI‑Ly1 (GCB type) cells, the effects of doxorubicin on reducing cell viability 
were enhanced by miR‑197 transfection. In apoptosis assays, miR‑197 transfection enhanced doxorubicin‑induced 
apoptosis in SUDHL9 cells but not in OCI‑Ly1 cells, suggesting a chemosensitizing effect of miR‑197 in ABC DLBCL.
Conclusions: These results suggest the role of miR‑197 as a biomarker with potential therapeutic implications.
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Background
Diffuse large B-cell lymphoma (DLBCL) is the most 
common type of malignant lymphoma, accounting for 
30–40% of non-Hodgkin lymphoma cases [1]. DLBCL 
can be classified into two cell-of-origin (COO) sub-
types, i.e., germinal center B cell (GCB) and activated B 
cell (ABC) types, which exhibit different gene expression 
profiles and clinical outcomes [2–6]. ABC DLBCL is rec-
ognized as a more aggressive subtype despite treatment 
with standard chemotherapy with rituximab plus cyclo-
phosphamide, doxorubicin, vincristine, and prednisone 
(R-CHOP) [5]. Non-GCB DLBCL based on Hans and 
related algorithms using immunohistochemistry was 
inferior to GCB DLBCL regarding survival. In addition, 
non-GCB DLBCL is thought to represent ABC DLBCL 
with a defined gene expression signature [2, 3, 6] despite 
several inconsistent studies [7–9]. Although the clinical 
outcome of DLBCL can been distinctively improved with 
R-CHOP therapy, approximately 1/3 of DLBCL patients 
still experience relapse or refractoriness [10]. In this con-
text, various studies have been performed to uncover and 
validate useful biomarkers to predict chemotherapeutic 
responses and clinical outcomes of DLBCL patients at 
the gene and protein levels as well as the post-transcrip-
tional level of gene expression as modulated by microR-
NAs [11–13].
Doxorubicin is an anticancer drug in the anthracycline 
family and is used to treat various types of malignan-
cies, including breast carcinoma, soft tissue sarcomas, 
acute leukemia and non-Hodgkin lymphomas [14–16]. 
Several complex mechanisms, including topoisomerase 
II inhibition, DNA intercalation, free radical generation, 
and the activation of several transcription factors, includ-
ing cAMP responsive element binding protein 3-like 1 
(CREB3L1), have been proposed to explain the antitumor 
activity of doxorubicin [17–19]. These biologic processes 
are regulated by many genes, proteins and microRNAs, 
and the response to this drug depends on the cellular 
context as it contains various regulatory molecules at the 
protein, gene and microRNA levels.
MicroRNAs are small non-coding RNAs composed of 
20–24 nucleotides [20]. MicroRNAs are involved in many 
important biological processes, including cell prolifera-
tion, differentiation and apoptosis [21, 22], which might 
also be associated with critical oncogenic or tumor-sup-
pressive pathways in neoplastic disease [23–25]. There-
fore, the roles of microRNAs have been investigated in 
various types of solid and hematologic tumors, includ-
ing DLBCL [26, 27], where distinct expression profiles 
were shown for GCB and ABC subtypes [28–30]. Sev-
eral microRNAs are known to influence the sensitivity 
of tumor cells to anticancer drugs, consequently affect-
ing the clinical outcomes of patients with hepatocellular 
carcinoma and chronic lymphocytic leukemia [31, 32]. 
MiR-451 is associated with doxorubicin resistance in 
breast cancer cells [33]. MiR-21 and miR-34a are regula-
tors of chemosensitivity in DLBCL [34, 35]. Furthermore, 
miR-18a, miR-181a, miR-222, miR-199a and miR-497 
predict overall and/or progression-free survival of 
DLBCL patients [36, 37].
Another important regulator of cancer-associated 
signaling in various solid and hematologic neoplasms is 
miR-197, which is involved in various pathways of can-
cer progression and chemoresistance depending on cell 
type and cellular context. MiR-197 regulates the response 
to 5-fluorouracil treatment in gastric and colorectal 
cancers via targeting mitogen-activated protein kinase 
1 and thymidylate synthase, respectively [38, 39]. MiR-
197 suppresses the p53-dependent apoptosis pathway in 
lung cancers [40] but induces apoptosis in myeloma cells 
via targeting Mcl-1 [41]. However, the role of miR-197 
in DLBCL has not clearly been elucidated to date with 
respect to prognosis and chemoresistance.
In the present study, we aimed to investigate the effects 
of miR-197 in response to chemotherapy in DLBCL 
patients and to determine the possibility of miR-197 as 
an adjuvant therapeutic agent to enhance the effect of 
doxorubicin in DLBCL patients, especially those with the 
ABC subtype.
Methods
Patients and human tissue specimens
A total of 51 patients diagnosed with DLBCL at Seoul 
National University Hospital from 2006 to 2012 and 
Seoul National University Hospital from 2003 to 2012 
were enrolled. The patients’ histologic slides and clinical 
medical records were retrospectively reviewed. Accord-
ing to the 2008 WHO classification of lymphoma, pri-
mary CNS lymphoma and mediastinal large B-cell 
lymphoma were excluded [42]. All DLBCL cases were 
divided into GCB and non-GCB subtypes using the Hans 
algorithm based on immunohistochemical findings [6]. 
The follow-up duration ranged from 0.5 to 64  months 
(median, 20.7  months). Twelve patients (24%) had pro-
gression and died at the time of analysis. Progression was 
defined as refractoriness, relapse or death. Progression-
free survival (PFS) was defined as the time from first 
treatment to lymphoma progression, including death of 
any cause [43]. The institutional review board approved 
this study.
Cell lines and reagents
SUDHL9 and OCI-LY1 are human DLBCL cell lines. 
SUDHL9 cells were cultured in Roswell Park Memo-
rial Institute 1640 (RPMI 1640) supplemented with 10% 
inactivated fetal bovine serum (WELGENE, Seoul, South 
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Korea) and 1% antibiotic–antimycotic solution (WEL-
GENE) in a humidified atmosphere with 5%  CO2 in air 
at 37  °C. OCI-LY1 cells were cultured in Iscove’s Modi-
fied Dulbecco’s Medium (WELGENE) supplemented 
with 20% inactivated fetal bovine serum and 1% antibi-
otic–antimycotic solution. Doxorubicin (Cat no. D1515, 
Sigma-Aldrich, St. Louis, MO, USA) was purchased from 
Sigma-Aldrich.
RNA extraction from formalin‑fixed tissues and cell lines
Total RNA was extracted from FFPE tissue samples using 
a RecoverAll™ Total Nucleic Acid Isolation for FFPE kit 
(Cat no. AM197, Applied Biosystems, Foster City, CA, 
USA) according to the manufacturer’s protocol and was 
stored at − 80  °C until the time of use after measuring 
the concentration with a NanoDrop 2000 spectropho-
tometer (Thermo Fisher Scientific, Waltham, MA, USA). 
Total RNA was extracted from DLBCL cell lines using 
TRI REAGENT (Cat no. TR118, Molecular Research 
Center, Cincinnati, OH, USA). MicroRNA was evaluated 
by qRT-PCR using Mir-X microRNA first strand synthe-
sis and the SYBR qRT-PCR kit (Cat no. 638313, Clontech 
Laboratories, Mountain View, CA, USA). U6 served as an 
internal control.
Screening of microRNAs using a microarray chip test 
in DLBCL tissues
To screen distinctly expressed microRNAs in DLBCL, 
microRNA expression profiles in 10 formalin-fixed 
paraffin-embedded (FFPE) DLBCL tissue samples 
were investigated using a peptide nucleic acid (PNA)-
based microRNA expression profiling kit (PANArray™, 
#PM-1001, version 1, Panagene, Daejeon, South Korea) 
containing 135 probes for cancer-related microRNAs 
according to the manufacturer’s instruction. U6 was 
included in the microarray slide as an internal control 
for normalization. The average value of the duplicate 
tests was used for expression profiling analysis. In this 
chip-based screening study, 73 microRNAs significantly 
expressed in DLBCL tissues were included in hierarchi-
cal clustering analysis of the agglomerative type (average 
linkage clustering). The DLBCL cases and microRNAs 
were reordered and clustered using the ‘heatmap.2’ func-
tion in the ‘gplots’ package in R using Euclidean meas-
urements to obtain a distance matrix and the complete 
average agglomeration method [44].
Quantitative real‑time polymerase chain reaction
Levels of hsa-miR-197 (cat no. 4427975, Applied Bio-
systems) were determined by qRT-PCR using TaqMan 
Universal PCR Master Mix and the TaqMan microRNA 
Reverse Transcription kit (Cat no. 4366596, Applied Bio-
systems), and U6 snRNA served as an internal control. 
The expression levels of the microRNAs were compared 
using 11 normal tonsil FFPE tissues as normal controls. 
The relative level of miR-197 in OSCC was calculated 
as  2−ΔΔCt, where ΔCt = Ct (miR-197) − Ct (U6) and 
ΔΔCt = ΔCt (tumor) − ΔCt (normal).
Cell culture and transfection of microRNA mimics
SUDHL9 and OCI-LY1 cells were seeded at a density of 
3 × 105  cells/well in 12-well plates and were cultured in 
Opti-MEM (Gibco, Grand Island, NY, USA). For trans-
fection, the transfection agent Lipofectamine 2000 
(Invitrogen, Waltham, MA, USA) and 50 and 100  nM 
microRNAs synthesized at GenePharma (Shanghai, 
China) were added to the cultured cells, and complemen-
tary media was added after 6 h.
Cell viability assay
SUDHL9 and OCI-LY1 cells were seeded at a density of 
3 × 105 cells/well in 12-well plates. At 24  h post-trans-
fection, various concentrations (0–100 nM for SUDHL9; 
0–200  nM for OCI-LY1) of doxorubicin were added to 
the cells, resulting in a total volume of 1000  µl/well. At 
48 h after doxorubicin treatment, 200 µl of treated cells 
were transfer to 96-well plates. Twenty microliters of EX-
CYTOX (EX-3000, DOGEN Bio., Seoul, South Korea) 
agent was added to each well. Then, the cells were main-
tained in an incubator with 5%  CO2 at 37  °C for 2–3 h. 
The absorbance at 450  nm, which is indicative of cell 
viability, was detected. All reactions were analyzed in 
triplicate.
Apoptosis assay
SUDHL9 and OCI-LY1 cells were treated with the same 
transfection conditions. Twenty-four hours post-trans-
fection, SUDHL9 cells were treated with 25 and 50  nM 
doxorubicin for 48  h, and OCI-LY1 cells were treated 
with 50, 100 and 200 nM doxorubicin for 72 h. For analy-
sis of apoptosis, cells were stained with 3 µl of Annexin 
V and 1.5 µl of PI for 10 min at RT in the dark using the 
FITC Annexin V Apoptosis Detection Kit I (556547, BD 
Biosciences, San Jose, CA, USA). All reactions were ana-
lyzed in triplicate using BD flow cytometry (BD FACS-
calibur, BD Biosciences).
Statistical analysis
The microRNA expression data obtained from microar-
ray chip assays for ten cases of DLBCL were analyzed by 
hierarchical clustering with dendrograms using R pack-
age 3.1.2 (gplots). Dot plots for comparison of microRNA 
expression levels between subgroups were also generated 
by R package 3.1.2 (ggplot2 and beeswarm). Other sta-
tistical analyses were performed using SPSS 21.0 (IBM, 
Armonk, NY, USA). All experiments were independently 
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performed in triplicate. Independent sample t-tests were 
used for comparison of microRNA expression levels. 
Survival data were analyzed using Kaplan–Meier analysis 
with log-rank tests and Cox proportional hazard models. 
p-values less than 0.05 were considered statistically sig-
nificant. MiR-197 expression was categorized as high or 
low expression based on the cutoff point exhibiting maxi-
mum χ2 (minimum p-value) as a prognostic factor [45]. 
This method employs a systematic search of almost all 
observed values as the candidate cutoff point and selects 
the value associated with a maximum χ2 (or minimum p 
value) as the final cutoff point [45].
Results
Screening of distinctively expressed microRNAs 
and identification of miR‑197 in DLBCL
By analyzing expression profiling using the cancer-
related microRNA microarray platform, six microRNAs 
(miR-197, miR-296-3p, miR-202, miR-185, miR-206 and 
miR-198) were recognized to form a distinctive clus-
ter in DLBCLs, as shown in the heatmap with dendro-
grams generated using a hierarchical clustering algorithm 
(Fig.  1 and Additional file  1: Figure S1). Among the six 
microRNAs, miR-197 exhibited the most distinctive pat-
tern in the cluster, and miR-197 expression levels exhib-
ited wide ranges among the various subtypes of DLBCLs. 
Therefore, we focused on the quantitative analysis of 
miR-197 to investigate its clinicopathologic association in 
DLBCLs.
Clinicopathologic features of diffuse large B cell lymphoma 
patients
The clinicopathologic features of 51 cases of DLBCL are 
presented in Table  1. Among the 51 cases of DLBCL, 
22% (11/51) were EBV positive. Old age (≥ 60  years), 
male patients, extranodal cases and low international 
prognostic index (IPI) were common features, account-
ing for approximately 60% of cases. Based on the Hans 
algorithm, 73% (37/51) of cases were classified as the 
non-GCB type, which included all 11 cases of EBV-pos-
itive DLBCL. R-CHOP therapy was administered to 84% 
(43/51) of patients.
MiR‑197 expression levels according to different 
clinicopathologic groups
As shown in Fig. 2a–d and Table 2, miR-197 expression 
levels were compared between various subgroups and 
clinicopathologic factors of DLBCL, i.e., EBV-positive 
vs. EBV-negative cases; GCB vs. non-GCB/ABC type; 
and nodal vs. extranodal cases. Based on comparisons of 
mean values using independent t-tests, miR-197 expres-
sion levels were not significantly associated with EBV 
status, nodal/extranodal, stages (I, II vs. III, IV) and IPI 
(0–2 vs. 3–5). The non-GCB subtype tended to have low 
miR-197 expression levels, but the result did not achieve 
statistical significance (p = 0.253).
Differential expression levels of miR‑197 based 
on progression status
MiR-197 expression levels were compared between the 
patients who had progression, i.e., refractoriness, relapse, 
or death, and those who did not exhibit progression dur-
ing the follow-up period (Fig.  2e, f ). Patients who pro-
gressed exhibited significantly low miR-197 levels in the 
R-CHOP-treated cohort (p = 0.004; n = 43), whereas the 
difference was not significant in the full cohort (p = 0.137; 
n = 51).
Associations among progression status, GCB/non‑GCB 
subtype and miR‑197 expression
Considering the significant effects of miR-197 on pro-
gression within the non-GCB subgroup, we analyzed the 
frequencies of progression among the three molecular 
groups, i.e., GCB, non-GCB/miR-197low and non-GCB/
miR-197high groups. As shown in Fig. 3, progression was 
most frequently noted in the non-GCB/miR-197low group 
in the full cohort (p = 0.013) and the R-CHOP cohort 
(p = 0.008).
Survival analysis of progression‑free survival based 
on miR‑197 expression levels
Given the close relationship between progression sta-
tus and miR-197 expression level, the effects of miR-
197 and various clinicopathologic variables on PFS were 
analyzed using the Kaplan–Meier method with log-rank 
tests. As shown in Fig. 4, the GCB type tended to have a 
good prognosis without statistical significance (p = 0.107; 
Fig. 4a), whereas low IPI was significantly associated with 
longer PFS (p < 0.001; Fig.  4b). The miR-197low group 
exhibited reduced PFS compared with the miR-197high 
group in the full cohort (n = 51; n = 0.040; Fig.  4c) and 
its non-GCB subgroup (n = 37; p = 0.016; Fig. 4d) as well 
as the R-CHOP cohort (n = 43; p = 0.036; Fig. 4e) and its 
non-GCB subgroup (n = 31; p = 0.020; Fig.  4f ). In con-
trast, the prognostic significance of miR-197 was not evi-
dent in the GCB subgroup of the full cohort or R-CHOP 
cohort (p > 0.05).
Progression‑free survival analysis based on miR‑197 
expression levels and clinicopathologic prognostic factors 
in the R‑CHOP cohort
Table  3 summarizes the prognostic factors predicting 
PFS using univariate and multivariate analysis in the 
R-CHOP cohort (n = 43) and ABC subgroup (n = 31). In 
the R-CHOP cohort, miR-197 was associated with PFS in 
univariate analysis. Other prognostic factors included IPI, 
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Fig. 1 Heatmap with dendrograms generated by hierarchical clustering in DLBCLs. Based on a hierarchical clustering algorithm, six microRNAs 
(miR‑197, miR‑296‑3p, miR‑202, miR‑185, miR‑206 and miR‑198) were distinctively clustered irrespective of DLBCL subtypes. MiR‑197 is marked with 
a red arrow
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B symptoms, bone marrow involvement, stage, perfor-
mance status, lactate dehydrogenase (LDH), and extran-
odal site number. Multivariate analysis revealed that IPI 
(p = 0.009; HR = 10.0), miR-197 (p = 0.031; HR = 27.9), 
and bone marrow involvement (p = 0.038; HR = 15.4) 
predicted PFS. In the non-GCB subgroup, univariate 
analysis revealed similar prognostic factors, including 
miR-197 and other clinicopathologic factors. Multivari-
ate analysis incorporating miR-197, IPI and bone marrow 
involvement revealed that miR-197 (p = 0.037; HR = 21.5) 
and bone marrow involvement (p = 0.046; HR = 13.5) 
were significant prognostic factors.
Cell viability assay after doxorubicin and miR‑197 
transfection treatment in DLBCL cell lines
Given the results from clinical samples demonstrat-
ing that miR-197 influenced the progression status and 
PFS, we hypothesized that miR-197 may be associated 
with chemoresistance in DLBCL tumor cells. Next, we 
selected two cell lines with low miR-197 expression 
to investigate the role of miR-197 in DLBCL cell lines 
treated with doxorubicin, a key tumoricidal component 
of the R-CHOP chemotherapeutic regimen. SUDHL9, 
an ABC type DLBCL cell line, and OCI-Ly1, a GCB type 
DLBCL cell line, cells were treated with doxorubicin with 
or without miR-197 mimic transfection. Upon transfec-
tion with the miR-197 mimic, cell viability significantly 
decreased after doxorubicin treatment in SUDHL9 and 
OCI-Ly1 cells compared with that in the scrambled con-
trol group (Fig. 5).
Apoptosis assay
In the apoptosis assay with Annexin V and propidium 
iodide (PI) staining using flow cytometry, the effects of 
miR-197 differed between SUDHL9 and OCI-Ly1 cells 
(Fig.  6). In SUDHL9 cells, miR-197 mimic transfec-
tion produced a significant increase in the proportion 
of apoptotic cells in the 25  nM doxorubicin treatment 
group, up to the similar level of the 50 nM doxorubicin 
treatment control group, suggesting a chemosensitizing 
effect of miR-197 (Fig. 6a, b). In contrast, OCI-Ly1 cells 
did not exhibit a significant difference in the proportion 
of apoptotic cells upon transfection with miR-197 mimic 
in each concentration group of doxorubicin treatment 
(Fig. 6c, d). Therefore, miR-197 might have an important 
role in doxorubicin chemosensitivity by enhancing doxo-
rubicin-induced apoptosis in SUDHL9, an ABC DLBCL 
cells. This finding is consistent with the results from 
patient samples from the R-CHOP cohort and the ABC 
subgroup.
Table 1 Clinicopathologic characteristics of diffuse large B 
cell lymphoma patients
IPI international prognostic index, ECOG PS Eastern Cooperative Oncology 
Group Performance Status, LDH lactate dehydrogenase, BM bone marrow, 
EBER EBV-encoded RNA, GCB germinal center B-like, CHOP cyclophosphamide, 
doxorubicin, vincristine, and prednisone
a These variables exclude missing values
Variables Full cohort (n = 51) R‑CHOP cohort (n = 43)
Number of cases (%) Number of cases (%)
Age, years
 Mean (range) 59.6 (21–85)
  < 60 21 (41%) 17 (40%)
  ≥ 60 30 (59%) 26 (60%)
Sex
 Male 30 (59%) 24 (56%)
 Female 21 (41%) 19 (44%)
Primary site
 Nodal 18 (35%) 14 (33%)
 Extranodal 33 (65%) 29 (67%)
Ann Arbor stage
 I, II 27 (53%) 23 (54%)
 III, IV 24 (37%) 20 (46%)
IPI  groupa
 Low (0–2) 30 (60%) 27 (63%)
 High (3–5) 20 (40%) 16 (37%)
B  symptomsa
 Absent 31 (62%) 29 (67%)
 Present 19 (38%) 14 (33%)
ECOG  PSa
 0, 1 40 (82%) 37 (86%)
 ≥ 2 9 (18%) 6 (14%)
LDHa
 Normal 21 (42%) 19 (44%)
 Elevated 29 (58%) 24 (56%)
BM  involvementa
 Absent 42 (91%) 38 (93%)
 Present 4 (9%) 3 (7%)
Number of extranodal  sitesa
 0, 1 40 (80%) 33 (77%)
 ≥ 2 10 (20%) 10 (23%)
EBER
 Negative 40 (78%) 36 (84%)
 Positive 11 (22%) 7 (16%)
Hans classification
 GCB 14 (27%) 12 (28%)
 Non‑GCB 37 (73%) 31 (72%)
Treatment
 Rituximab + CHOP 43 (84%) 43 (100%)
 Rituximab + others 1 (2%) 0 (0%)
 Surgery only 2 (4%) 0 (0%)
 No Tx 5 (10%) 0 (0%)
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Discussion
Treatment outcome of DLBCL has been considerably 
improved given the development of combination chem-
otherapy and the introduction of rituximab. However, 
approximately 1/3 of patients with DLBCL still experi-
ence relapse or refractoriness after standard therapy, 
eventually exhibiting a very poor outcome [10]. Among 
the numerous clinical and molecular subtypes of DLBCL, 
the ABC subtype exhibits a high rate of relapse or refrac-
toriness, and targeting strategies focusing on the ABC 
subtype are being developed while its clinical utility 
still remains to be validated [46, 47]. Considering that 
Fig. 2 Relative miR‑197 expression level based on clinicopathologic variables and progression status. Relative miR‑197 expression levels did not 
differ based on Hans classification (a), EBV infection (b), primary site (c) or Ann Arbor stage (d) in the full cohort of diffuse large B‑cell lymphoma (n 
= 51). MiR‑197 levels tended to be reduced in the progression group compared with the no progression group in the full cohort (n = 51) (e). In the 
R‑CHOP cohort (n = 43), miR‑197 was significantly reduced in the progression group (f)
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microRNAs interfere with multiple targets involved in 
cell survival and drug resistance, we focused on the role 
of miR-197 in DLBCL and investigated whether it could 
determine the responsiveness of standard R-CHOP ther-
apy and enhance the sensitivity of doxorubicin in DLBCL 
cells. In the present study, we observed that (1) miR-197 
expression levels were significantly low in the DLBCL 
progression group, (2) low miR-197 levels were associ-
ated with shorter PFS in the R-CHOP cohort and ABC 
subgroup, and (3) miR-197 enhanced doxorubicin sensi-
tivity in SUDHL9 cells of the ABC subtype.
MiR-197 is involved in apoptosis in solid tumors and 
hematologic neoplasms. In lung cancers, miR-197 sup-
presses apoptosis in a p53-dependent manner, playing 
an oncogenic role [40]. In contrast, a different role of 
miR-197 in apoptosis is noted in hematologic cells. In 
myeloma cells, miR-197 and miR-137 induce apoptosis 
by targeting Mcl-1 [41]. The researchers focused on fre-
quent loss of the 1p12-21 region containing miR-137/
miR-197 genes and demonstrated reduction of Mcl-1 
protein and induction of apoptosis upon transfection of 
miR-137/miR-197 into myeloma cells as well as in  vivo 
tumor regression by intratumoral injection of miR-137/
miR-197 in a xenograft murine model of myeloma. The 
inhibiting effect of miR-197 to Mcl-1 may also be at least 
partly effective in ABC DLBCL because gain or amplifica-
tion of the Mcl-1 gene was noted in 26% of ABC DLBCL 
[48]. ABC DLBCLs are thought to be derived from B cells 
at a plasmablastic stage frequently expressing genes of 
mature plasma cells [49, 50] and exhibit CBM complex 
(CARD11, BCL10, and MALT1)-driven constitutive acti-
vation of NF-κB signaling [51, 52], which is a key onco-
genic signaling pathway that activates Mcl-1 in multiple 
myeloma [53].
Another important oncogenic signaling pathway in 
ABC DLBCL is the cytokine signaling/Janus kinase–
signal transducer and activator of transcription (JAK–
STAT) pathway [49]. A study using ABC DLBCL cells 
revealed that aberrant expression of IL-22 receptor 1 
and IL-22 stimulation increased STAT3 and ERK1/2 
activation, suggesting the important pathogenic roles 
of the IL-22/IL-22R1/STAT3 pathway in ABC DLBCL 
[54]. Remarkably, miR-197 reduces STAT3 signaling via 
miR-197/IL-22/STAT3 and miR-197/IL-6/STAT3 path-
ways in human keratinocytes and hepatocellular carci-
nomas [55, 56]. In addition, MyD88 mutations occur in 
> 30% of ABC DLBCL cases and activate both NF-κB 
and JAK–STAT signaling pathways [57], both of which 
participate in anti-apoptosis, cell survival and chem-
oresistance [49, 58, 59].
DLBCL exhibits heterogeneous clinical outcomes 
and molecular alterations [49]. The wide distribution 
of miR-197 expression levels in our data may reflect 
Table 2 Comparison of miR-197 expression levels 
according to clinicopathologic characteristics in diffuse 
large B cell lymphoma patients
IPI international prognostic index, ECOG PS Eastern Cooperative Oncology Group 
Performance Status, LDH lactate dehydrogenase, BM bone marrow, EBER EBV-
encoded RNA, GCB germinal center B-like
a These variables exclude missing values
Variables Full cohort (n = 51) R‑CHOP cohort 
(n = 43)
Mean ± SD p value Mean ± SD p value
Age, years 0.415 0.357
 < 60 18.2 ± 32.6 7.8 ± 12.0
 ≥ 60 12.0 ± 13.7 11.6 ± 13.4
Sex 0.603 0.353
 Male 16.0 ± 27.7 8.5 ± 10.4
 Female 12.5 ± 15.4 12.2 ± 15.4
Primary site 0.504 0.595
 Nodal 11.5 ± 15.3 8.6 ± 14.3
 Extranodal 16.2 ± 26.8 10.8 ± 12.3
Ann Arbor stage 0.379 0.731
 I, II 17.3 ± 29.2 10.7 ± 12.8
 III, IV 11.5 ± 14.1 9.4 ± 13.2
IPI  groupa 0.664 0.985
 Low (0–2) 11.2 ± 13.0 10.1 ± 12.3
 High (3–5) 13.0 ± 15.6 10.1 ± 14.1
B  symptomsa 0.737
 Absent 15.7 ± 27.4 10.4 ± 12.2
 Present 13.4 ± 15.6 9.5 ± 14.4
ECOG  PSa 0.886 0.310
 0, 1 12.0 ± 13.8 10.9 ± 13.5
 ≥ 2 12.8 ± 16.0 5.1 ± 5.9
LDHa 0.466 0.785
 Normal 10.2 ± 13.2 9.5 ± 12.6
 Elevated 13.2 ± 14.6 10.6 ± 13.3
BM  involvementa 0.561 0.452
 Absent 11.0 ± 12.5 9.1 ± 11.2
 Present 19.2 ± 24.8 24.1 ± 27.9
Number of extranodal 
 sitesa
0.182 0.582
 0, 1 12.9 ± 15.0 10.7 ± 14.0
 ≥ 2 8.1 ± 8.0 8.1 ± 8.0
EBER 0.820 0.804
 Negative 14.1 ± 24.4 9.9 ± 11.2
 Positive 16.0 ± 19.8 11.2 ± 20.4
Hans classification 0.253 0.833
 GCB 20.7 ± 38.0 9.4 ± 11.5
 Non‑GCB 12.2 ± 14.6 10.4 ± 13.5
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the heterogeneous molecular nature of DLBCL and its 
ABC subtype. Considering that microRNAs constitute 
complex multiple network of signaling pathways [60], 
relative expression levels of miR-197 may indicate inhi-
bition of NF-κB/Mcl-1 and STAT3 signaling in ABC 
DLBCL, suggesting the possible role of miR-197 as a 
biomarker of progression in DLBCL, especially in the 
ABC subtype.
DLBCL heterogeneity was also demonstrated in hier-
archical clustering analysis of microRNA chip-based 
expression profiling, where the cases were not clustered 
based on disease type or EBV status. This finding may 
partly be associated with the general cancer-related but 
not lymphoma-specific properties of the microRNA 
panel and the relatively small number of cases ana-
lyzed. Based on this type of screening, we observed that 
Fig. 3 Comparison of relative miR‑197 expression levels and frequency of patients with progression in the GCB, non‑GCB/miR‑197low and non‑GCB/
miR‑197high subgroups of diffuse large B‑cell lymphoma. Compared with the GCB and non‑GCB/miR‑197high subgroups exhibiting similar levels 
of miR‑197 expression, the non‑GCB/miR‑197low subgroup exhibited low miR‑197 levels and high progression rates in full cohort (a) and R‑CHOP 
cohort (b)
(See figure on next page.)
Fig. 4 Survival curves for progression‑free survival in diffuse large B‑cell lymphoma. The non‑germinal center B‑like (non‑GCB) subtype tended 
to exhibit shorter progression‑free survival (PFS) compared with the GCB subtype (a), whereas a high international prognostic index (IPI) was a 
significant predictor of shorter PFS (b) in the R‑CHOP cohort (n = 43). Low miR‑197 levels were also associated with shorter PFS in the full cohort 
(n = 51) (c) and its non‑GCB subgroup (n = 37) (d) as well as the R‑CHOP cohort (n = 43) (e) and its non‑GCB subgroup (n = 31) (f)
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a miR-197 was distinctively identified and was associ-
ated with lymphoma progression and chemoresistance, 
which could be a cancer-related property, as demon-
strated in the clinicopathologic analysis with clinical 
samples and the in vitro assays.
In vitro studies using the SUDHL9 cell line of the 
ABC subtype revealed that the effect of low-level 
(25  nM) doxorubicin treatment was approximately 
equivalent to treatment with twice (50 nM) the concen-
tration. This effect might suggest the possibility of miR-
197 as a chemosensitizing adjuvant agent to reduce 
doxorubicin concentrations, which might provide the 
same tumor-killing effect and reduce the cardiac toxic-
ity associated with doxorubicin. This strategy to sup-
plement miR-197 requires further clarification with 
pre-clinical and clinical studies.
Table 3 Univariate and multivariate survival analysis of clinicopathologic variables and miR-197 expression in diffuse 
large B cell lymphoma patients
UA univariate analysis, MA multivariate analysis, 95% CI 95% confidence interval, IPI international prognostic index, LDH lactate dehydrogenase
a These variables were not included in multivariate analysis due to their close relationship with IPI
Clinicopathologic variables R‑CHOP cohort, n = 43 ABC R‑CHOP cohort, n = 31
UA MA UA MA
p p HR [95% CI] p p HR [95% CI]
miR‑197
 Low vs. high 0.036 0.031 27.9 [1.4–569.0] 0.025 0.037 21.5 [1.2–382.6]
IPI
 High (3–5) vs. low (0–2) < 0.001 0.009 10.0 [1.8–56.1] 0.001 0.055 5.1 [1.0–26.6]
B symptoms
 Presence vs. absence 0.024 0.844 1.2 [0.3–4.8] 0.059
Bone marrow involvement
 Presence vs. absence 0.006 0.038 15.4 [1.2–203.3] 0.029 0.046 13.5 [1.1–173.1]
Stagea
 I–II vs. III–IV 0.004 0.012
Performance  statusa
 ≥ 2 vs. 0–1 < 0.001 < 0.001
LDHa
 Elevated vs. normal 0.005 0.005
Number of extranodal  sitesa
 ≥ 2 vs. 0–1 < 0.001 0.002
Fig. 5 Cell viability assay results for doxorubicin treatment and miR‑197 transfection in diffuse large B‑cell lymphoma cell lines. Upon treatment 
with a series of doxorubicin concentrations in diffuse large B‑cell lymphoma cells of non‑germinal center/activated B cell‑like (non‑GCB/ABC; 
SUDHL9) phenotype and GCB origin (OCI‑LY1), cell viability was significantly reduced in the miR‑197 transfection group compared with that in the 
scrambled control group. SUDHL9, an ABC DLBCL cell line, exhibited significant miR‑197‑transfection‑induced reduction in cell viability at lower 
concentrations of doxorubicin (a) compared with OCI‑Ly1, a GCB DLBCL cell line (b)
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In our in  vitro investigation, we focused on the role 
of miR-197 in doxorubicin sensitivity because doxoru-
bicin is an essential component of chemotherapeutic 
regimens that kill aggressive B lymphoma cells, includ-
ing the standard R-CHOP regimen as well as R-EPOCH 
(rituximab, etoposide, prednisone, vincristine, cyclo-
phosphamide and doxorubicin) and hyper-CVAD 
(course A: cyclophosphamide, vincristine, doxorubicin, 
and dexamethasone; course B: methotrexate and cyta-
rabine) [61]. Moreover, sufficient doses of doxorubicin 
are critical for clinical outcome in DLBCL patients [62]. 
It still remains to be clarified further whether miR-197 
may also influence the effects on sensitivity of other 
drugs.
Conclusions
Taken together, the results in our study suggests the 
clinicopathologic implication of miR-197 in DLBCL. 
Low miR-197 expression is associated with frequent 
progression and reduced PFS in DLBCL after stand-
ard R-CHOP therapy, especially in the ABC subtype. 
In vitro studies reveal a chemosensitizing effect of miR-
197 in SUDHL9 cells of the ABC subtype treated with 
doxorubicin. These findings suggest a possible role of 
miR-197 as a useful biomarker to predict progression 
and as a chemosensitizer to enhance therapeutic effi-
cacy, providing insight into effective therapeutic strate-
gies with detailed risk assessment in DLBCL.
Fig. 6 Apoptosis assay results for doxorubicin treatment and miR‑197 transfection in diffuse large B‑cell lymphoma cell lines. Measurement of 
apoptotic cell proportions upon transfection of miR‑197 in SUDHL9, an activated B cell‑like diffuse large B‑cell lymphoma (ABC DLBCL) cell line, 
revealed the induction of a significant chemosensitizing effect to 25 nM doxorubicin treatment as shown in the bar graph (a) and representative 
flow cytometry plot (b), whereas no significant difference was observed in OCI‑LY1, a germinal center B‑like DLBCL cell line, as shown in the bar 
graph (c) and representative flow cytometry plot (d)
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